SOFT

Closed

IBCSG 24-02/BIG 2-02: SOFT

BCT Study Chair:

Prue Francis

A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.

2826

INTERNATIONAL

Total number of trial

participants internationally

240

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

51

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

SOFT PUBLICATIONS

2023

Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in pre-menopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.

Brown LC, Luen SJ, Molania R, Caramia F, Savas P, VanGeelen C, Chic N, Fleming GF, Kammler R, Colleoni M, Viale G, Speed TP, Regan MM, Francis PA, Loi S. Journal of Clinical Oncology 2023; 41(suppl 16):Oral Abstract 504, Abstract

Genomic characterisation of hormone receptor-positive breast cancer arising in young women.

Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell’Orto P, Biasi O, Degasperi A, Brown LC, Lang I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Muller B, Joshum W, Bonnefoi H, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman R, Solbach C, Thurlimann B, Colleoni M, Coates AS, Goldhirsch A, Fleming GF, Francis PA, Speed TP, Regan MM, Loi S. Annals of Oncology. 2023; epub 25 January 2023, doi: 10.1016/j.annonc.2023.01.009;, E-pub

2022

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials.

Pagani* O, Walley* BA, Francis GF, Colleoni M, Láng I, Gomez Hl, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winder EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan** MM, Francis** PA, for the SOFT and TEXT Investigators and the International Breast Cancer Study Group. *Co-lead authors. **Co-last authors. Journal of Clinical Oncology. 2022; Epub 15 December 2022. doi: 10.1200/JCO.22.01064, E-pub

Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT.

Francis* PA, Fleming* GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE Jr, Walley BA, Ingle, JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM, for the SOFT Investigators and the International Breast Cancer Study Group. *Co-lead authors. Journal of Clinical Oncology. 2022; Epub 9 December 2022. doi: 10.1200/JCO.22.01065., E-pub

Back to the Beginning: The role of ovarian suppression in management of hormone sensitive breast cancer in premenopausal women.

Connolly RM, Miller RD. Journal of Clinical Oncology. 2022; epub 15 December 2022 doi: 10.1200/JCO.22.02319., Editorial

Genomic characterisation of hormone receptor-positive, HER2-negative breast cancer arising in young women: a secondary analysis of the SOFT trial.

Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell-Orto P, Biasi O, Degasperi A, Brown LC, Lang I, Tondini C, Ezquerra MB, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Gliment MA, Muller BG, , Jochum W, Bonnefoi HR, Martino S, Davidson NE, Geyer CE, Chia SK, Ingle JN, Coelman R, Solbach C, Thuerlimann B, Colleoni M, Coates A, Goldhirsch A, Fleming GF, Francis P, Speed TP, Regan M, Loi S. San Antonio Breast Cancer Symposium. 2022; Abstract# PD17-10, Abstract

SOFT